The retinoic acid receptors (RARs) have an important role in cell differentiation and death. Retinoic acid induces differentiation of neuroblastoma cells in vitro, a property that has led to the successful use of 13-cis retinoic acid, a prodrug for all-trans retinoic acid, 1 in the treatment of minimum residual disease of neuroblastoma patients. 2 All three RAR subtypes (a, b and g) can be activated by all-trans or 9-cis retinoic acid, and these receptors function as heterodimers with retinoid-X receptors (RXRs) to enhance or drive the expression of target genes. 3 Unlike the all-trans isomer, 9-cis retinoic acid activates both RARs and RXRs. Retinoic acid analogues (retinoids) with a narrower selectivity for the RAR subtypes are undergoing clinical and laboratory evaluation. One such retinoid is fenretinide (n-(4-hydroxyphenyl) retinamide), which is RARb-and RARg-selective. Unlike retinoic acid, fenretinide is able to induce apoptosis in a range of neuroblastoma cell lines, including some which are resistant to retinoic acid. 4 This makes fenretinide a potentially powerful agent for the treatment of neuroblastoma.
The induction of caspase-3-dependent death of neuroblastoma cells by fenretinide is linked to the activation of ceramide signalling pathways, 12-lipoxygenase activity and the induction of free radicals. 5 RARb/g-selective antagonists inhibit fenretinide-driven death of neuroblastoma cells 6 and this suggests that RARs may also be involved. Gel shift assays suggest that heterodimers of RARg and RXRb predominate in the neuroblastoma cell model used for our fenretinide studies. 7 Since retinoic acid induces differentiation of neuroblastoma cells, 8 fenretinide-induced death of these cells may result from activation of RARg in combination with fenretinidegenerated free radicals or oxidative stress. This hypothesis leads to two predictions: (1) increased expression of RARg should increase cell death in response to fenretinide, and (2) increased levels of RARg would not affect cell death in response to retinoic acid since retinoic acid isomers induce differentiation without increasing oxidative stress. 9 To test these predictions, we developed an SH-SY5Y cell model in which RARg is conditionally induced in response to tetracycline antibiotics. Two cell clones, SH-SY5Y
Tet12-S2 (Tet12-S2) and SH-SY5Y
Tet12-S4 (Tet12-S4) showing strong induction of RARg 24 h after addition of tetracyclines (tetracycline or the more-stable and water-soluble analogue doxycycline) were selected and characterised (Figure 1a ). The induction of RARg was stable for at least 24 h after washout of the tetracycline inducer (Figure 1a) . The Tet12-S2 and Tet12-S4 clones had similar characteristics with respect to the induction of RARg and were both used for experiments ( Figure 1a) . As with the parental SH-SY5Y cells, 6 the apoptotic effects of fenretinide may be mediated at least in part by RARg since the RARb/g antagonists CD2848 and CD2665 inhibited the effects of fenretinide in reducing cell culture density ( Figure 1b) .
Although doxycycline at concentrations up to 4 mg/ml decreased the density of parental SH-SY5Y cell cultures, at 1 mg/ml the effect was small and not significantly different (P40.25) from control cells. In contrast, over a similar timescale doxycycline reduced the density of Tet12-S4 cell cultures to 75.8% (76.2) of vehicle-treated control cells (t 8 ¼ À7.63, Po0.0001; Figure 1c ). Since the RARg-inducible cells were otherwise more resistant to apoptosis-inducing agents such as fenretinide, with IC 50 values for fenretinide of around 3.5 mM compared to 0.5-1 mM for the parental SH-SY5Y cells, this suggests that overexpression of RARg, rather than the doxycycline inducer, reduced the rate of cell proliferation.
To test the hypothesis that RARg is involved in fenretinideinduced cell death, RARg-inducible cells were treated with fenretinide in the presence or absence of 1 mg/ml doxycycline to induce RARg. There was a clear effect of fenretinide in reducing culture density with increasing dose (ANOVA, F 4,290 ¼ 48.6, Po0.0001; Figure 1d , upper graph), but, contrary to our prediction that overexpression of RARg would decrease the density of fenretinide-treated cultures still further, induction of RARg expression resulted in a slight increase in cell density compared to uninduced cells (F 1,290 ¼ 4.6, P ¼ 0.033; Figure 1d , upper graph). Flow cytometry of propidium-iodide-stained cells was used to measure apoptosis after treatment with fenretinide in the presence or absence of doxycycline to induce overexpression of RARg, and this showed no significant difference between RARg-induced and -uninduced cells in their apoptotic response to fenretinide (F 1,8 ¼ 3.224, P ¼ 0.11; Figure 1d , lower graph). Therefore, it is clear that overexpression of RARg did not increase the apoptotic or antiproliferative effect of fenretinide in the way predicted.
The failure of RARg overexpression to increase fenretinideinduced apoptosis was unexpected given evidence from RARb/g antagonists that RARs are involved in mediating fenretinide effects. 6 Since retinoic acid isomers also reduce the rate of proliferation of SH-SY5Y cells, a result of cell 8 we asked whether overexpression of RARg would affect the response of these cells to retinoic acid. Tet12-S2 cells were responsive to alltrans retinoic acid, and these cells were more elongated with longer cell processes after treatment with 1 mM all-trans retinoic acid for 3 days (Figure 1e ). Fenretinide had a slight effect on cell morphology, producing more-angular cells with less prominent lamellipodia and an increased number of apoptotic bodies. In cultures treated with fenretinide in combination with RARg induction, the cells were more similar (Figure 1e) . Conversely, treatment with all-trans retinoic acid after induction of RARg overexpression changed the morphology of these cells to a rounder, flatter phenotype reminiscent of Stype neuroblastoma cells with an increase in the number of apoptotic bodies (Figure 1e) . Treatment of the Tet12-S2 cells with all-trans or 9-cis retinoic acid after induction of RARg gave 3.2-fold and 1.85-fold increases in cell death, respectively, relative to retinoic acid-treated cells without overexpression of RARg (Figure 1f, upper graph) . Similar results were obtained with Tet12-S4 cells where, relative to cells treated with retinoic acid without RARg overexpression, a 3.8-fold increase in cell death resulted after treatment of RARg-induced cells with 2.4 mM all-trans retinoic acid (Figure 1f, lower graph) .
The unexpected finding from these experiments was the morphological change and induction of cell death in response to ligand-activation of overexpressed RARg. Treatment of the parental SH-SY5Y cells with all-trans or 9-cis retinoic acid leads to differentiation without an increase in cell death. 8 Although the removal of 9-cis retinoic acid from differentiated SH-SY5Y cells induces cell death, 10 this may be attributed to an induced dependence on neurotrophic factors conditionally expressed in response to retinoic acid. 11 The induction of apoptosis in response to retinoic acid in the context of increased expression of RARg could be interpreted in terms of the thymocyte model developed by Szondy et al. 12 According to this model, increased activation of RARg alters the balance of RARa:RARg activation in favour of proapoptotic effects of RARg. 12 Therefore, increased expression of RARg coupled with the presence of ligand would be predicted to achieve the same effect. Unlike apoptosis in thymocytes, 13 9-cis retinoic acid was less effective than alltrans retinoic acid, suggesting that RXR activation is not involved or has an inhibitory role. Alternatively, the morphological effects after ligand-activation of overexpressed RARg may indicate a transition to a cell phenotype where apoptosis is a consequence of retinoic acid treatment, as has been reported for S-type neuroblastoma cells. 14 In contrast to recent results for squamous carcinoma cells, 15 RARg overexpression did not significantly affect fenretinide-induced apoptosis, and this suggests that RARg activation by fenretinide does not have a major role in apoptosis of neuroblastoma cells. One possibility is that, despite its minor contribution to RAR-RXR heterodimers in these cells, 7 RARb may be involved in apoptosis. Alternatively, the ability of RARb/g (but not RARa 6 ) antagonists to block fenretinide-induced apoptosis may not be mediated directly by RARs. Clearly, the role of RARs in fenretinideinduced apoptosis in neuroblastoma and other cell types needs critical re-evaluation. However, apoptosis resulting from the retinoic acid-dependent activation of overexpressed RARg has important implications for the potential of RARspecific ligands in the treatment of neuroblastoma and other cancers. Furthermore, the inhibition of retinoic acid-induced neuritogenesis by RARg overexpression in SH-SY5Y and other neuroblastoma cell lines 16 raises fundamental questions concerning the role of RARs in specifying neuronal phenotype. 
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